Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1975 1
1977 2
1981 2
1982 2
1983 2
1984 3
1985 4
1986 2
1987 4
1988 3
1989 2
1990 10
1991 3
1992 2
1993 4
1994 9
1995 9
1996 8
1997 6
1998 9
1999 8
2000 4
2001 4
2002 11
2003 10
2004 9
2005 16
2006 9
2007 15
2008 16
2009 14
2010 17
2011 7
2012 23
2013 20
2014 17
2015 22
2016 12
2017 15
2018 20
2019 15
2020 12
2021 11
2022 17
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

388 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, Sonika U, Dalal A. Jain A, et al. Hepatology. 2022 May;75(5):1194-1203. doi: 10.1002/hep.32255. Epub 2021 Dec 21. Hepatology. 2022. PMID: 34822189 Clinical Trial.
BACKGROUND AND AIMS: Data on the use of intravenous L-ornithine L-aspartate (LOLA) in the treatment of overt HE (OHE) is limited. We evaluated the role of intravenous LOLA in patients of cirrhosis with OHE grade III-IV. ...
BACKGROUND AND AIMS: Data on the use of intravenous L-ornithine L-aspartate (LOLA) in the treatment of overt HE (OHE) is limited. We …
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.
Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Baandrup L, et al. Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD011481. doi: 10.1002/14651858.CD011481.pub2. Cochrane Database Syst Rev. 2018. PMID: 29543325 Free PMC article. Review.
Alpidem decreased the proportion of participants with benzodiazepine discontinuation (1 study, 25 participants; RR 0.41, 95% CI 0.17 to 0.99; number needed to treat for an additional harmful outcome (NNTH) 2.3 participants; low-quality evidence) and increased the occurrence of wi …
Alpidem decreased the proportion of participants with benzodiazepine discontinuation (1 study, 25 participants; RR 0.41, 95% CI 0.17 to 0.99 …
Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Reisberg B, et al. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi: 10.1056/NEJMoa013128. N Engl J Med. 2003. PMID: 12672860 Free article. Clinical Trial.
BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. ...
BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. .. …
Clinical effects of low-dose esketamine for anaesthesia induction in the elderly: A randomized controlled trial.
Li J, Wang Z, Wang A, Wang Z. Li J, et al. J Clin Pharm Ther. 2022 Jun;47(6):759-766. doi: 10.1111/jcpt.13604. Epub 2022 Jan 11. J Clin Pharm Ther. 2022. PMID: 35018643 Clinical Trial.
WHAT IS KNOWN AND OBJECTIVE: Esketamine is an N-methyl-D-aspartic acid (NMDA) receptor antagonist, which has stronger sedative and analgesic effects and fewer adverse events than ketamine. ...
WHAT IS KNOWN AND OBJECTIVE: Esketamine is an N-methyl-D-aspartic acid (NMDA) receptor antagonist, which has stronger sedative …
Effects of Supplementing Zinc Magnesium Aspartate on Sleep Quality and Submaximal Weightlifting Performance, following Two Consecutive Nights of Partial Sleep Deprivation.
Gallagher C, Austin V, Dunlop KA, Dally J, Taylor K, Pullinger SA, Edwards BJ. Gallagher C, et al. Nutrients. 2024 Jan 13;16(2):251. doi: 10.3390/nu16020251. Nutrients. 2024. PMID: 38257144 Free PMC article. Clinical Trial.
Purpose: We examined whether supplementation of zinc magnesium aspartate (ZMA), while partially sleep deprived, was beneficial to sleep quality and subsequent morning (07:00 h) submaximal weightlifting. ...Main effect for "load" on the bar was found, where AP and tP …
Purpose: We examined whether supplementation of zinc magnesium aspartate (ZMA), while partially sleep deprived, was beneficial …
Effect of acute potassium-magnesium aspartate supplementation on ammonia concentrations during and after resistance training.
Tuttle JL, Potteiger JA, Evans BW, Ozmun JC. Tuttle JL, et al. Int J Sport Nutr. 1995 Jun;5(2):102-9. doi: 10.1123/ijsn.5.2.102. Int J Sport Nutr. 1995. PMID: 7670449 Clinical Trial.
This study examined the effects of aspartate supplementation (ASP) on plasma ammonia concentrations ([NH4+]) during and after a resistance training workout (RTW). ...
This study examined the effects of aspartate supplementation (ASP) on plasma ammonia concentrations ([NH4+]) during and after a resis …
Effect of treatment with magnesium and potassium on mortality and reinfarction rate of patients with suspected acute myocardial infarction.
Singh RB, Singh NK, Niaz MA, Sharma JP. Singh RB, et al. Int J Clin Pharmacol Ther. 1996 May;34(5):219-25. Int J Clin Pharmacol Ther. 1996. PMID: 8738859 Clinical Trial.
The aim of the study was to test whether magnesium and potassium administration can decrease both early and late cardiac event rates in 355 patients with suspected acute myocardial infarction (AMI). ...After discharge from the hospital all groups were advised to fol …
The aim of the study was to test whether magnesium and potassium administration can decrease both early and late cardiac event …
388 results